Accueil>>Signaling Pathways>> Neuroscience>> Histamine Receptor>>Wy 49051

Wy 49051

Catalog No.GC31824

Wy 49051 est un puissant antagoniste des récepteurs H1 actif par voie orale, avec une IC50 de 44 nM.

Products are for research use only. Not for human use. We do not sell to patients.

Wy 49051 Chemical Structure

Cas No.: 113418-56-7

Taille Prix Stock Qté
1mg
276,00 $US
En stock
5mg
552,00 $US
En stock
10mg
937,00 $US
En stock
20mg
1 655,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Wy 49051 is a potent, orally active H1 receptor antagonist, with IC50 of 44 nM.

Wy 49051 shows great inhibitory effect on H1, producing 92% inhibition of the histamine-induced contraction of the guinea pig ileum at a concentration 100 nM. Wy 49051 is the most potent compound with 700 times the potency of astemazole, 470 times the potency of chlorpheniramine. Wy 49051 also has high affinity for α1 receptor with IC50 of 8 nM[1].

Wy 49051 shows potent activity against histamine-induced lethality in the guinea pig, with ED50 of 1.91 mg/kg by po, 0.70 mg/kg by ip, and 0.01 mg/kg by iv. The duration of action of 24 is also favorable since there is no decrease in oral efficacy up to 18 h posttreatment[1].

[1]. Abou-Gharbia M, et al. New antihistamines: substituted piperazine and piperidine derivatives as novel H1-antagonists. J Med Chem. 1995 Sep 29;38(20):4026-32.

Avis

Review for Wy 49051

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Wy 49051

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.